Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
This study aims to demonstrate the possible benefit of a treatment based on double diuretic
in patients with chronic kidney disease and severely impaired glomerular filtration rate.
This is based on previous observations where the investigators found that volume overload is
a frequent condition within this population and is strongly linked to an increase in
morbidity and mortality. The investigators consider that this therapy could be beneficial
given that most of these patients are treated with loop diuretics, however, with the passage
of time, adaptive changes in the distal nephron occur that promote a decrease in the
treatment effect. In this sense, thiazide diuretics at appropriate doses could 'break' the
resistance, since their mechanism of action antagonizes the resistance mechanism.
Unfortunately, to this day, this treatment has not been fully evaluated. Particularly in this
type of population.
The investigators developed a study proposed as a double blind randomized clinical trial,
where the population will be divided into two groups. A group will be given the standard
treatment based on loop diuretic (bumetanide), while the other group will receive the
intervention (bumetanide plus chlorthalidone). After a 30-day follow-up period, the results
will be measured.
With respect to the effectiveness of the treatment, the decrease in volume overload by
bioimpedance will be measured. While the occurrence of adverse effects during the same
monitoring period will be observed.